Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Lasme-cel achieved a 100% overall response rate (ORR) in the target Phase 2 population for relapsed/refractory B-cell acute lymphoblastic leukemia in the BALLI-01 Phase 1 trial. — A 100% ORR in a heavily pretreated population with limited options is a very strong clinical signal that significantly increases the probability of success for the upcoming pivotal study.
+0.80
2
Preliminary data for eti-cel in r/r B-cell non Hodgkin lymphoma showed an 88% ORR and 63% complete response rate in the optimal dose cohort of the NATHALI-01 study. — Strong early efficacy for a dual-targeting allogeneic CAR-T in a difficult-to-treat population expands the company's potential pipeline value.
+0.60
3
Cellectis expects the first interim analysis of the Pivotal Phase 2 BALLI-01 trial in Q4 2026. — Provides a concrete near-term catalyst date for investors to expect the next major value-inflection event.
+0.30

Which stocks this story touches

6 related stories

Cellectis Presents Final… — CLLS +0.80 | NewsImpactScreener